Results 61 to 70 of about 2,363,412 (175)

A novel method of thrombelastograph analysis aids assessment of antiplatelet therapy in percutaneous coronary intervention. [PDF]

, 2010
MD (Research)Background A near-patient test of responses to antiplatelet therapy would be of great value in percutaneous coronary intervention (PCI). However, at present, there are no widely accepted tests and varied definitions of “resistance”.
Hobson, Alex
core   +1 more source

Aspirin resistance in patients with acute coronary syndrome. Part 1

Кардиоваскулярная терапия и профилактика, 2010
Aim. To evaluate the prevalence of aspirin resistance, its clinical features, potential solutions, and prognostic role in patients with acute coronary syndrome (ACS). Material and methods. The study included 51 patients with ACS and ST segment elevation (
N. S. Frolova, R. M. Shakhnovich, E. M. Kaznacheeva, O. V. Sirotkina, A. B. Dobrovolsky   +4 more
doaj  

Aspirin Resistance after CABG

, 2009
Background: Temporary aspirin resistance can occur during the post-CABG period. If the factors causing resistance can be identified, the incidence of early graft occlusions can also be minimized. Methods: 25 elective CABG cases were enrolled in the study.
TETİK, ŞERMİN, M. Yilmaz, H. Deniz, S. Tetik, I. Arslan, S. Sanioglu, O. Sokullu, F. Bilgen, N. Aydemir   +8 more
core   +1 more source

Effect of Opium Addiction on Aspirin Resistance in Stable Angina Pectoris [PDF]

Addiction and Health, 2014
Background: The rate of cardiovascular diseases in developing countries is approximately 60% and it is still has an increasing trend. The clinical effectiveness of aspirin in preventing cardiovascular events has been well proven.
Afsaneh Forood, Reza Malekpour-Afshar, Jamshid Sarnevesht   +2 more
doaj  

Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner

Stem Cell Research & Therapy, 2020
Background The widely recognized anti-cancer potential of aspirin has created a broad interest to explore the clinical benefits of aspirin in cancer therapy.
Xiaoyuan Zhang, Renle Du, Na Luo, Rong Xiang, Wenzhi Shen   +4 more
doaj   +1 more source

Prevalence rate of aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis

Caspian Journal of Internal Medicine, 2020
Background: Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all the healthcare systems facing this very challenging issue.
Parvin Ebrahimi, Zeynab Farhadi, Masoud Bahzadifar, Hosein Shabaninejad, Hasan abolghasem gorji, Masood Tahermi mirghaed, Morteza Salemi, Kamyar Amin, Roghayeh Mohammadibakhsh, Nicola Luigi Bragazzi, Rahim Sohrabi   +10 more
doaj  

Aspirin resistance and compliance with therapy

, 2010
Introduction: Aspirin resistance is associated with increased cardiovascular risk in aspirin-treated patients. Poor compliance may explain many cases of "resistance," yet few clinical studies have used objective measurement of therapy compliance.
Higgins, P., Walters, M.R., Gautamanda Ray, Dawson, J., Ray, G., Jesse Dawson, Quinn, T.J, Lees, K.R., Terry Quinn, Peter Higgins, Kennedy R. Lees, Rafferty, M., Matthew R. Walters, Mark Rafferty   +13 more
core   +1 more source

Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness

Thoracic Cancer, 2020
Background Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin. Although cisplatin treatment may initially be successful, its effectiveness usually reduces significantly in disease‐recurrent patients.
Maoyuan Zhao, Ting Wang, Zhouguang Hui
doaj   +1 more source

Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels

Thrombosis Journal, 2005
Background To be fully activated platelets are dependent on two positive feedback loops; the formation of thromboxane A2 by cyclooxygenase in the platelets and the release of ADP.
Öhlin Hans, van Heusden Catharina, Lazarowski Eduardo, Borna Catharina, Erlinge David   +4 more
doaj   +1 more source

Antiplatelet activity should be measured routinely: no [PDF]

, 2009
Antiplatelet agents such as aspirin, clopidogrel, anddipyridamole are effective in secondary stroke pre-vention with single agents reducing risk by 15 % to 20%1–3; the addition of a second agent (eg, combining aspirin and dipyridamole) doubles this ...
Philip M. W. Bath, Bath, Philip M.W.
core   +1 more source